m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00433)
Name
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide
Synonyms
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide; Kinome_3019; CHEMBL210032; SCHEMBL1145340; BDBM15968; Aminopyridine-Based Inhibitor 24
    Click to Show/Hide
Status
Investigative
Structure
Formula
C14H12N4O
InChI
1S/C14H12N4O/c1-9(19)17-13-7-12(16)11(8-15)14(18-13)10-5-3-2-4-6-10/h2-7H,1H3,(H3,16,17,18,19)
InChIKey
GTMGQYXCPKUZAD-UHFFFAOYSA-N
PubChem CID
11658882
TTD Drug ID
D0S7IE
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cyclin-dependent kinase 2 (CDK2)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [2]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cyclin-dependent kinase 2 (CDK2) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Cyclin-dependent kinase 2 (CDK2). [1], [2]
Inhibitor of nuclear factor kappa-B kinase alpha (IKKA)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Inhibitor of nuclear factor kappa-B kinase alpha (IKKA) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Inhibitor of nuclear factor kappa-B kinase alpha (IKKA). [4], [5]
Stress-activated protein kinase JNK1 (JNK1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). [4], [6]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). [6], [7]
References
Ref 1 FTO regulates adipogenesis by controlling cell cycle progression via m(6)A-YTHDF2 dependent mechanism. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Oct;1863(10):1323-1330. doi: 10.1016/j.bbalip.2018.08.008. Epub 2018 Aug 13.
Ref 2 Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. doi: 10.1016/j.bmcl.2006.04.071. Epub 2006 May 6.
Ref 3 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.
Ref 4 METTL3 regulates alternative splicing of MyD88 upon the lipopolysaccharide-induced inflammatory response in human dental pulp cells. J Cell Mol Med. 2018 May;22(5):2558-2568. doi: 10.1111/jcmm.13491. Epub 2018 Mar 4.
Ref 5 Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. doi: 10.1093/nar/gkr797. Epub 2011 Sep 24.
Ref 6 Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. doi: 10.1021/jm060199b.
Ref 7 Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response. Nucleic Acids Res. 2021 Jun 4;49(10):5779-5797. doi: 10.1093/nar/gkab415.